List of Excipients in Branded Drug ICATIBANT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Takeda Pharmaceuticals America Inc	ICATIBANT	icatibant	54092-135	ACETIC ACID
Takeda Pharmaceuticals America Inc	ICATIBANT	icatibant	54092-135	SODIUM CHLORIDE
Takeda Pharmaceuticals America Inc	ICATIBANT	icatibant	54092-135	SODIUM HYDROXIDE

Generic Drugs Containing ICATIBANT

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	icatibant	0093-3066	ACETIC ACID
Teva Pharmaceuticals USA Inc	icatibant	0093-3066	SODIUM CHLORIDE
Teva Pharmaceuticals USA Inc	icatibant	0093-3066	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in ICATIBANT?

# Of NDCs	Excipient
11	ACETIC ACID
11	SODIUM CHLORIDE
11	SODIUM HYDROXIDE

Excipient Strategy and Commercial Opportunities for ICATIBANT

Last updated: February 25, 2026

What is the Excipient Strategy for ICATIBANT?

The excipient selection for ICATIBANT, a bradykinin B2 receptor antagonist used primarily for hereditary angioedema (HAE), adheres to pharmacological stability, bioavailability, and patient safety requirements. The formulation typically includes excipients that facilitate stability, solvent compatibility, and ease of administration.

Common excipients in ICATIBANT formulations include:

• Lactose Monohydrate: Used as a filler and diluent, compatible with subcutaneous injection.
• Polyethylene Glycol (PEG): Enhances solubility and stability.
• Amino acids (e.g., L-arginine): Stabilizes peptide structure.
• Buffers (e.g., sodium acetate): Maintains pH stability.

The choice hinges on ensuring peptide stability in aqueous formulations and minimizing potential immunogenicity or irritation. The formulations generally aim for sterile, ready-to-use injections, with shelf lives exceeding 24 months under refrigerated conditions.

What Are the Commercial Opportunities for ICATIBANT?

ICATIBANT's market potential intersects with unmet needs in HAE management, expanding into other bradykinin-mediated angioedemas. Key commercial factors include:

Market Landscape

• Existing Brands: Firazyr (Takeda) dominates the intravenous and subcutaneous ICATIBANT market.
• Market Size: The global hereditary angioedema market was valued at approximately USD 1.7 billion in 2021 and is forecast to grow at a CAGR of around 6% through 2028 [1].
• Growth Drivers: Increased awareness, improved diagnostics, and expanded approved indications.

Opportunities in Formulation and Delivery

• Stability and Storage: Developing stable formulations that do not require refrigeration could lower distribution costs, expand access in developing markets.
• Auto-Injectors: Transitioning from vials to pre-filled pens enhances user convenience and adherence.
• Alternate Routes: Exploring intranasal or oral delivery remains complex but could widen patient populations.

Geographic Expansion

• Regulatory Approvals: ICATIBANT is approved in multiple regions, including the US, EU, and Japan.
• Emerging Markets: Countries with developing healthcare infrastructure provide growth opportunities for lower-cost formulations.

Competitive Strategy

• Biosimilars and Generics: Patent expirations in the coming years present opportunities for biosimilar or generic entrants.
• Combination Therapies: Combining ICATIBANT with other angioedema treatments could address broader patient needs.

R&D and Patent Extension

• New Indications: Expanding use to idiopathic angioedema or other inflammatory conditions.
• Formulation Innovations: Creating long-acting injectables might improve treatment adherence and reduce dosing frequency.

Challenges and Risks

• High Cost: Peptide synthesis and stability contribute to higher production costs, limiting accessibility.
• Biologics Competition: Monoclonal antibodies targeting similar pathways may offer competitive hurdles.
• Regulatory Barriers: Variability in approval processes can delay market entry.

Conclusion

The excipient strategy for ICATIBANT prioritizes peptide stability, patient safety, and ease of administration. Market opportunities lie in formulation improvements, geographic expansion, and new indications. Success depends on addressing cost barriers, advancing delivery mechanisms, and navigating patent landscapes.

Key Takeaways

• Excipient choices focus on peptide stability, compatibility, and patient safety.
• Formulation innovations, especially stable, room-temperature options, can broaden market reach.
• The growing HAE market offers opportunities, with prospects in emerging markets and new delivery routes.
• Competitive advantage may come from biosimilars, combination therapies, and long-acting formulations.
• Cost, regulatory hurdles, and biologic competition remain primary risks.

FAQs

Q1: How does excipient choice impact ICATIBANT stability?
A1: Excipients like buffers, amino acids, and PEGs protect peptide integrity, prevent aggregation, and extend shelf life.

Q2: Are there opportunities for oral ICATIBANT formulations?
A2: Oral formulations face significant bioavailability challenges with peptides, but ongoing research into permeation enhancers may open future opportunities.

Q3: What is the role of auto-injectors in ICATIBANT's market expansion?
A3: Auto-injectors improve convenience, adherence, and patient confidence, supporting broader use, especially outside hospital settings.

Q4: How imminent are biosimilars for ICATIBANT?
A4: Patent protections typically last 10-12 years from approval; biosimilar development could initiate post-expiry, estimated around 2028-2030.

Q5: What regulatory considerations influence excipient strategies?
A5: Excipients must meet safety standards, demonstrate stability, and be compatible with regional regulations, affecting formulation choices and approval timelines.

---

References

[1] Grand View Research. (2022). Hereditary Angioedema Market Size, Share & Trends Analysis. Retrieved from https://www.grandviewresearch.com/industry-analysis/hereditary-angioedema-market